Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | XDH | P47989 | 1/20 | 0.41 |
| ▸ | GRIN2D | O15399 | 5/20 | 0.39 |
| ▸ | GRIN3B | O60391 | 5/20 | 0.39 |
| ▸ | GRIN1 | Q05586 | 5/20 | 0.39 |
| ▸ | GRIN2A | Q12879 | 5/20 | 0.39 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.39 |
| ▸ | GRIN2C | Q14957 | 5/20 | 0.39 |
| ▸ | GRIN3A | Q8TCU5 | 5/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27476008 | 0.75 | CYP3A4 (0.50) | MEN1KMT2ACYP3A4NAMPTXDH | |
| SCHEMBL4608324 | 0.75 | ALDH1A1 (0.51) | MEN1KMT2ACYP3A4NAMPTXDH | |
| SCHEMBL11097776 | 0.75 | PARP1 (0.35) | MEN1KMT2APARP1ALDH1A1TDP1 | |
| SCHEMBL6579710 | 0.74 | KMT2A (0.77) | MEN1KMT2ACYP3A4NAMPTXDH | |
| SCHEMBL6142552 | 0.72 | CYP3A4 (0.46) | MEN1KMT2ACYP3A4NAMPTXDH | |
| SCHEMBL6581227 | 0.72 | FABP6 (0.44) | MEN1KMT2AGRIN2DGRIN3BGRIN1 | |
| SCHEMBL6581516 | 0.72 | KDM4E (0.39) | CYP3A4XDHPARP1ALDH1A1TDP1 | |
| SCHEMBL27949142 | 0.71 | MAPT (0.44) | MEN1KMT2ACYP3A4GRIN2DGRIN3B | |
| SCHEMBL4918988 | 0.70 | TDP1 (0.52) | MEN1KMT2ACYP3A4GRIN2DGRIN3B | |
| SCHEMBL7016746 | 0.70 | CYP3A4 (0.56) | MEN1KMT2ACYP3A4NAMPTXDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1037887-B1 | 5-(2-IMIDAZOLINYLAMINO)-BENZIMIDAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS .ALPHA.-ADRENOCEPTOR AGONISTS WITH IMPROVED METABOLIC STABILITY | PROCTER & GAMBLE (US) | 2004-07-14 | — | — | EP | disclosed |
| US-6486190-B1 | 5-(2-imidazolinylamino)-benzimidazole derivatives, their preparation and their use as .alpha.-adrenoceptor agonists with improved metabolic stability | THE PROCTER & GAMBLE COMPANY | 2002-11-26 | — | — | US | disclosed |
| CN-1284073-A | 5- (2-imidazolinylamino) -benzimidazole derivatives, their preparation and their use as alpha-adrenergic receptor agonists with improved metabolic stability | PROCTER & GAMBLE (US) | 2001-02-14 | — | — | CN | disclosed |
| EP-1037887-A1 | 5-(2-IMIDAZOLINYLAMINO)-BENZIMIDAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS .ALPHA.-ADRENOCEPTOR AGONISTS WITH IMPROVED METABOLIC STABILITY | THE PROCTER & GAMBLE COMPANY (US) | 2000-09-27 | — | — | EP | disclosed |
| CN-1256691-A | 5-(2-imidazolinylamino) benzimidazole compounds useful as alpha-2 adrenoceptor agonists | PROCTER & GAMBLE (US) | 2000-06-14 | — | — | CN | disclosed |
| EP-0975627-A1 | 5-(2-IMIDAZOLINYLAMINO)BENZIMIDAZOLE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 2000-02-02 | — | — | EP | disclosed |
| WO-1999026942-A1 | 5-(2-IMIDAZOLINYLAMINO)-BENZIMIDAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS .ALPHA.-ADRENOCEPTOR AGONISTS WITH IMPROVED METABOLIC STABILITY | THE PROCTER & GAMBLE COMPANY (US) | 1999-06-03 | — | — | WO | disclosed |
| WO-1998046595-A1 | 5-(2-IMIDAZOLINYLAMINO)BENZIMIDAZOLE COMPOUNDS USEFUL AS ALPHA-2 ADRENOCEPTOR AGONISTS | THE PROCTER & GAMBLE COMPANY (US) | 1998-10-22 | — | — | WO | disclosed |